Literature DB >> 32271988

Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia.

Songping Cui1, Shuo Chen1, Xiunan Li1, Shi Liu2, Feng Wang3,4,5,6.   

Abstract

BACKGROUND: Three months ago, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) broke out in Wuhan, China, and spread rapidly around the world. Severe novel coronavirus pneumonia (NCP) patients have abnormal blood coagulation function, but their venous thromboembolism (VTE) prevalence is still rarely mentioned.
OBJECTIVES: To determine the incidence of VTE in patients with severe NCP.
METHODS: In this study, 81 severe NCP patients in the intensive care unit (ICU) of Union Hospital (Wuhan, China) were enrolled. The results of conventional coagulation parameters and lower limb vein ultrasonography of these patients were retrospectively collected and analyzed.
RESULTS: The incidence of VTE in these patients was 25% (20/81), of which 8 patients with VTE events died. The VTE group was different from the non-VTE group in age, lymphocyte counts, activated partial thromboplastin time (APTT), D-dimer, etc. If 1.5 µg/mL was used as the D-dimer cut-off value to predicting VTE, the sensitivity was 85.0%, the specificity was 88.5%, and the negative predictive value (NPV) was 94.7%.
CONCLUSIONS: The incidence of VTE in patients with severe NCP is 25% (20/81), which may be related to poor prognosis. The significant increase of D-dimer in severe NCP patients is a good index for identifying high-risk groups of VTE.
© 2020 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  D-dimer; blood coagulation; coagulation parameter; novel coronavirus pneumonia; venous thromboembolism

Mesh:

Substances:

Year:  2020        PMID: 32271988      PMCID: PMC7262324          DOI: 10.1111/jth.14830

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


The prevalence of venous thromboembolism (VTE) in patients with severe novel coronavirus pneumonia (NCP) is still unknown. Conventional coagulation parameters and ultrasound results of lower extremity veins in patients with severe NCP were retrospectively analyzed. The incidence of VTE in the intensive care unit of patients with severe NCP is 25% (20/81), which may be related to poor prognosis. The level of D‐dimer was a good index for predicting VTE in patients with severe NCP.

INTRODUCTION

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is a new type of respiratory transmitted virus. By mid‐March 2020, it had sickened more than 80 000 people and killed more than 3000 in China, triggering a global pandemic. A number of studies have shown that coagulation dysfunction exists in patients with severe novel coronavirus pneumonia (NCP), , , , which is clearly correlated with poor prognosis. The conventional coagulation parameters of intensive care unit (ICU) patients were significantly higher than those of non‐ICU patients. However, the prevalence of venous thromboembolism (VTE) in ICU patients with severe NCP is unknown. Therefore, the purpose of this study was to explore the incidence of VTE in such patients and to investigate the differences between VTE patients and non‐VTE patients.

METHODS

A total of 81 patients diagnosed with NCP in the ICU of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology from January 30 to March 22, 2020, were included. All the patients were diagnosed according to the World Health Organization guidelines. The severity of NCP was judged according to the Fifth Revised Trial Version of the Novel Coronavirus Pneumonia Diagnosis and Treatment Guidance. The patients were subjected to a series of investigations, including clinical examinations, laboratory tests, chest computed tomography (CT), lower limb venous doppler ultrasound, and real‐time reverse transcriptase polymerase chain reaction (rRT‐PCR) for SARS‐CoV‐2. All the patients received antiviral and supportive treatment after diagnosis, and no preventive anticoagulant was administered. The study was approved by the Ethics Committee of Union Hospital (Wuhan, China). Conventional coagulation tests, which included prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), international normalized ratio (INR), fibrinogen (FIB), and D‐dimer were performed using a Succeeder SF8200 automatic coagulation analyzer (China). Clinical and laboratory information was also collected. Data are presented as means ± standard deviation (SD) or number (percentage) where appropriate. T test or Mann‐Whitney U test were used to analyze the differences between the two groups. P < .05 was defined as statistically significant. Statistical analysis was conducted using SPSS software version 21.0 (IBM).

RESULTS AND DISCUSSION

A total of 81 patients with severe NCP were enrolled in this study, with the mean age of 59.9 years (range, 32‐91 years), including 44 females (54%). Thirty‐three (41%) patients had chronic medical illness, including hypertension, diabetes, and coronary heart disease; 35 (43%) patients had a history of smoking. As of 22 March, 64 (79%) patients had been discharged from hospital, 8 (10%) had died, and the rest (9; 11%) remained hospitalized (Table 1).
Table 1

Baseline characteristics of NCP patients (n = 81)

CharacteristicNumber (%) or mean (SD)
Age, years59.9 (14.1)
Range32‐91
≤3911 (14%)
40‐4911 (14%)
50‐5913 (16%)
60‐6928 (35%)
≥7018 (22%)
Sex
Male37 (46%)
Female44 (54%)
Chronic medical illness
Hypertention20 (25%)
Diabetes8 (10%)
Coronary heart disease10 (12%)
Smoking35 (43%)
Clinical outcome
Remained in hospital9 (11%)
Discharged64 (79%)
Died8 (10%)

Abbreviation: NCP, novel coronavirus pneumonia; SD, standard deviation.

Baseline characteristics of NCP patients (n = 81) Abbreviation: NCP, novel coronavirus pneumonia; SD, standard deviation. A total of 20 (25%) patients with severe NCP developed lower extremity venous thrombosis, of which 8 patients died. The VTE group had older age (68.4 ± 9.1 versus 57.1 ± 14.3 years, P < .001), lower lymphocyte counts (0.8 ± 0.4 versus 1.3 ± 0.6 × 109/L, P < .001), longer APTT (39.9 ± 6.4 versus 35.6 ± 4.5 seconds, P = .001), and higher D‐dimer (5.2 ± 3.0 versus 0.8 ± 1.2 µg/mL, P < .001). Moreover, the D‐dimer of the two groups was not within the normal range (Table 2).
Table 2

Characteristics between the VTE and non‐VTE groups (n = 81)

CharacteristicsNormal rangeVTE (n = 20)Non‐VTE (n = 61) P‐value
Age (years)68.4 ± 9.157.1 ± 14.3<.001
Leucocytes (×109/L)3.5‐9.57.8 ± 3.16.6 ± 2.6.120
Lymphocytes (×109/L)1.1‐3.20.8 ± 0.41.3 ± 0.6<.001
Platelets (×109/L)125.0‐350.0246.6 ± 110.6248.8 ± 111.7.938
Haemoglobin (g/L)115.0‐150.0123.2 ± 16.5125.3 ± 16.7.633
APTT (s)27.0‐45.039.9 ± 6.435.6 ± 4.5.001
Prothrombin time (s)11.0‐16.015.4 ± 1.015.6 ± 1.0.465
D‐dimer (µg/mL)0.0‐0.55.2 ± 3.00.8 ± 1.2<.001

Abbreviation: APTT, activated partial thromboplastin time; VTE, venous thromboembolism.

Characteristics between the VTE and non‐VTE groups (n = 81) Abbreviation: APTT, activated partial thromboplastin time; VTE, venous thromboembolism. Table 3 shows the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of different D‐dimer levels in predicting VTE in patients with severe NCP. If 1.5 µg/mL was used as the cut‐off value for D‐dimer to predict VTE, the sensitivity, specificity, PPV, and NPV were 85.0%, 88.5%, 70.8%, and 94.7%, respectively (Table 3).
Table 3

Sensitivity, specificity, PPV, and NPV of different D‐dimer cut‐off levels for predicting VTE in NCP patients

Cut‐off (µg/mL)Sensitivity (%)Specificity (%)PPV (%)NPV (%)
1.085.077.054.894.0
1.585.088.570.894.7
2.080.090.272.793.2
2.570.093.477.890.5
3.070.096.787.590.8
3.565.096.786.789.4

Abbreviation: NCP, novel coronavirus pneumonia; NPV, negative predictive value; PPV, positive predictive value; VTE, venous thromboembolism.

Sensitivity, specificity, PPV, and NPV of different D‐dimer cut‐off levels for predicting VTE in NCP patients Abbreviation: NCP, novel coronavirus pneumonia; NPV, negative predictive value; PPV, positive predictive value; VTE, venous thromboembolism. In this study, the decrease of lymphocytes was common in patients with NCP, especially in patients with VTE. Other studies have also observed that infection with SARS‐CoV‐2 leads to lymphocytopenia. , , In the analysis of lymphocyte subset, T cells were more susceptible to SARS‐CoV‐2, because T cell count was almost half of the lower reference limit, and the severe NCP patients were more likely to be hampered. Moreover, abnormal expression of T cell associated mRNA can lead to VTE. This meant that older patients with more underlying diseases were more likely to develop immune dysfunction and have a higher risk of VTE because of their poor immunity. Severe SARS‐CoV‐2 infection in NCP patients can lead to sepsis, which can also lead to the release of inflammatory cytokines such as IL‐6, IL‐8, TNF‐α, etc, similar to severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). , Inflammatory cytokines can promote the activation of blood coagulation in many ways, and then promote the occurrence of VTE. , , Sepsis is also a common cause of disseminated intravascular coagulation (DIC) and the incidence of DIC in dead NCP patients was 71.4%. This suggests that abnormal blood coagulation and thrombosis are associated with poor prognosis in patients with NCP. Elevated D‐dimer level is a sign of excessive coagulation activation and hyperfibrinolysis. Therefore, D‐dimer is often used to detect active thrombus with high sensitivity but low specificity. But, if 3.0 µg/mL was used as the cut‐off value, the sensitivity, specificity, and NPV were 76.9%, 94.9%, and 92.5%, respectively. After receiving anticoagulant therapy, the level of D‐dimer decreased gradually, which means that D‐dimer can not only predict thrombosis but also monitor the effectiveness of anticoagulants. There are several limitations in our report. First, this is a retrospective, single‐center, small sample study. The results may be biased and need to be confirmed by a large sample study. Second, some patients are still being treated in hospital, and the clinical outcome may change. Despite that, our study described the incidence of VTE in patients with severe NCP and demonstrated the application of D‐dimer in VTE prediction. We hope that these results will contribute to the prevention, diagnosis, and treatment of VTE.

CONFLICTS OF INTEREST

The authors declare that they have no conflicts of interest.

AUTHOR CONTRIBUTIONS

XL and SL collected the clinical data. SPC and SC processed statistical data. SPC and SC drafted and revised the manuscript. FW designed and guided the study.
  15 in total

Review 1.  Interactions between coagulation and inflammation.

Authors:  Steven M Opal
Journal:  Scand J Infect Dis       Date:  2003

Review 2.  Present and future of anticoagulant therapy using antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation: a perspective from Japan.

Authors:  Toshiaki Iba; Jecko Thachil
Journal:  Int J Hematol       Date:  2015-11-20       Impact factor: 2.490

Review 3.  Crosstalk between inflammation and coagulation: the lessons of sepsis.

Authors:  Tom van der Poll; Marcel Levi
Journal:  Curr Vasc Pharmacol       Date:  2012-09       Impact factor: 2.719

4.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.

Authors:  Dawei Wang; Bo Hu; Chang Hu; Fangfang Zhu; Xing Liu; Jing Zhang; Binbin Wang; Hui Xiang; Zhenshun Cheng; Yong Xiong; Yan Zhao; Yirong Li; Xinghuan Wang; Zhiyong Peng
Journal:  JAMA       Date:  2020-03-17       Impact factor: 56.272

5.  Prominent changes in blood coagulation of patients with SARS-CoV-2 infection.

Authors:  Huan Han; Lan Yang; Rui Liu; Fang Liu; Kai-Lang Wu; Jie Li; Xing-Hui Liu; Cheng-Liang Zhu
Journal:  Clin Chem Lab Med       Date:  2020-06-25       Impact factor: 3.694

6.  Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China.

Authors:  Chuan Qin; Luoqi Zhou; Ziwei Hu; Shuoqi Zhang; Sheng Yang; Yu Tao; Cuihong Xie; Ke Ma; Ke Shang; Wei Wang; Dai-Shi Tian
Journal:  Clin Infect Dis       Date:  2020-07-28       Impact factor: 9.079

7.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors:  Chaolin Huang; Yeming Wang; Xingwang Li; Lili Ren; Jianping Zhao; Yi Hu; Li Zhang; Guohui Fan; Jiuyang Xu; Xiaoying Gu; Zhenshun Cheng; Ting Yu; Jiaan Xia; Yuan Wei; Wenjuan Wu; Xuelei Xie; Wen Yin; Hui Li; Min Liu; Yan Xiao; Hong Gao; Li Guo; Jungang Xie; Guangfa Wang; Rongmeng Jiang; Zhancheng Gao; Qi Jin; Jianwei Wang; Bin Cao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

8.  Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.

Authors:  Ning Tang; Dengju Li; Xiong Wang; Ziyong Sun
Journal:  J Thromb Haemost       Date:  2020-03-13       Impact factor: 5.824

9.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.

Authors:  Nanshan Chen; Min Zhou; Xuan Dong; Jieming Qu; Fengyun Gong; Yang Han; Yang Qiu; Jingli Wang; Ying Liu; Yuan Wei; Jia'an Xia; Ting Yu; Xinxin Zhang; Li Zhang
Journal:  Lancet       Date:  2020-01-30       Impact factor: 79.321

10.  Symptomatic venous thromboembolism is a disease related to infection and immune dysfunction.

Authors:  Qianglin Duan; Zhu Gong; Haoming Song; Lemin Wang; Fan Yang; Wei Lv; Yanli Song
Journal:  Int J Med Sci       Date:  2012-07-26       Impact factor: 3.738

View more
  654 in total

1.  Overview of the Haematological Effects of COVID-19 Infection.

Authors:  T M Wiggill; E S Mayne; J L Vaughan; S Louw
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Cutaneous Manifestations in Patients With COVID-19: Clinical Characteristics and Possible Pathophysiologic Mechanisms.

Authors:  F González González; C Cortés Correa; E Peñaranda Contreras
Journal:  Actas Dermosifiliogr       Date:  2021-01-28

3.  A toolkit for the collection of thrombosis-related data elements in COVID-19 clinical studies.

Authors:  Deborah M Siegal; Geoffrey D Barnes; Nicole J Langlois; Adrienne Lee; Saskia Middeldorp; Leslie Skeith; William A Wood; Grégoire Le Gal
Journal:  Blood Adv       Date:  2020-12-22

4.  Thrombotic risk in COVID-19: a case series and case-control study.

Authors:  Simon M Stoneham; Kate M Milne; Elisabeth Nuttall; Georgina H Frew; Beattie Rh Sturrock; Helena Sivaloganathan; Eleni E Ladikou; Stephen Drage; Barbara Phillips; Timothy Jt Chevassut; Alice C Eziefula
Journal:  Clin Med (Lond)       Date:  2020-05-18       Impact factor: 2.659

5. 

Authors:  Stephanie G Lee; Michael Fralick; Michelle Sholzberg
Journal:  CMAJ       Date:  2020-11-09       Impact factor: 8.262

6.  COVID-19 and its implication for venous thromboembolism.

Authors:  Michał Ciurzynski; Justyna Domienik-Karłowicz; Miłosz Jaguszewski; Piotr Pruszczyk
Journal:  Cardiol J       Date:  2020       Impact factor: 2.737

Review 7.  Thrombotic Risk and Covid-19: Review of Current Evidence for a Better Diagnostic and Therapeutic Approach.

Authors:  Raquel López-Reyes; Grace Oscullo; David Jiménez; Irene Cano; Alberto García-Ortega
Journal:  Arch Bronconeumol       Date:  2020-08-31       Impact factor: 4.872

8.  Coagulopathy associated with COVID-19.

Authors:  Stephanie G Lee; Michael Fralick; Michelle Sholzberg
Journal:  CMAJ       Date:  2020-05-01       Impact factor: 8.262

Review 9.  Coronavirus disease and the cardiovascular system: a narrative review of the mechanisms of injury and management implications.

Authors:  Maria Vega Brizneda; Agam Bansal; Vardhmaan Jain; Samir Kapadia; Lars G Svensson; Venu Menon; Paul Cremer; Grant Reed; Penelope Rampersad; Richard Grimm; Brian P Griffin; Bo Xu
Journal:  Cardiovasc Diagn Ther       Date:  2021-06

Review 10.  Review of Pharmacotherapy Trialed for Management of the Coronavirus Disease-19.

Authors:  Kimberly Hall; Fuhbe Mfone; Michael Shallcross; Vikas Pathak
Journal:  Eurasian J Med       Date:  2021-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.